Invitae Acquires Genosity In $200M Deal, Raises $1.15Bn From Softbank Group
Invitae continues its growth initiative with a $1.15bn investment from Softbank Group and acquisition of Genosity to accelerate oncology testing.
You may also be interested in...
Vicarious Surgical, whose medical robot received US FDA breakthrough designation, announced it will merge with D8 Holdings Corp. The deal is expected to garner up to $460m.
In this week’s podcast, Medtech Insight managing editor Marion Webb discusses plans by the Mayo Clinic and Veterans Health Administration to position themselves as medical device makers of 3D-printing technologies. UK-based reporter Barnaby Pickering gives an overview of global market for arthroscopy and sports medicine products.
The buyout will broaden DiaSorin’s positioning in the fast-growing molecular diagnostics space and expand Luminex’s foothold outside the US.